Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
26 Mai 2021 - 02:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced
that Ron Cooper, President and Chief Executive Officer, will
present as part of fireside chats at both the 2021 Jefferies
Virtual Healthcare Conference on Wednesday, June 2,
at 9:30 a.m. EDT and William Blair’s 41st Annual Growth Stock
Conference on Thursday, June 3, at 12:40 p.m. EDT. Members of the
management team will also host meetings with investors June 1-3.
The live webcast of both presentations will be accessible from
the Media & Investors page of Albireo’s website,
ir.albireopharma.com. To ensure a timely connection to the webcast,
it is recommended that users register at least 15 minutes prior to
the scheduled start time. An archived version of the webcasts will
be available for replay in the Events & Presentations section
of the Media & Investors page of Albireo’s website for at least
two weeks following the event.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, Bylvay, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3 trials
in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA
recently granted Priority Review and set a PDUFA goal date of July
20, 2021. In Europe, the EMA validated MAA. Bylvay is the only
IBATi granted accelerated assessment by the EMA. Bylvay has been
provisionally accepted by both the FDA and EMA as the brand name
for odevixibat. The Company has also initiated a Phase 1 clinical
trial for A3907 to advance development in adult cholestatic liver
disease, with IND-enabling studies moving ahead with A2342 for
viral and cholestatic liver disease. Albireo was spun out from
AstraZeneca in 2008 and is headquartered in Boston, Massachusetts,
with its key operating subsidiary in Gothenburg, Sweden. The Boston
Business Journal named Albireo one of the 2020 Best Places to Work
in Massachusetts for the second consecutive year. For more
information on Albireo, please visit www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024